ClinicalTrials.gg
CompletedNCT02294019Updated May 30, 2016Results posted

Actual Use Trial of Ibuprofen 400 mg

A Phase 3 interventional study of Ibuprofen 400 mg caplet in Patient Compliance, sponsored by Pfizer. Completed at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-30.

Sponsored by Pfizer · Phase 3 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
738
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 240 studies in Patient Compliance with a site in United States — 9 open to participants now, 19 under way, 1 of them phase 3. Patient Compliance · United States.

Enrollment
22nd of 201
738 · median 119
Started
2014
with 14 others
Phase 3
9 of 240
1 open now
Registered
136th of 240
by date

Among the 240 studies in Patient Compliance with a site in United States, this one is the 22nd largest by enrollment of the 201 interventional ones that give a count, is one of 15 that started in 2014, is one of 9 in phase 3, and was the 136th registered.

Patient Compliance

752 studies on the registry are indexed under Patient Compliance; 72 are open to participants now.

Browse Patient Compliance studies →

Open to participants now

9 of the 240 studies in Patient Compliance with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Patient Compliance studies recruiting now, 25 (56%) set no upper age limit and 13 (29%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 240 studies in Patient Compliance with a site in United States, or all of them as a file.
02

Study summary

This is an open label, multicenter, 30 day study designed to mimic an OTC like environment in which subjects will use the product after making a purchase decision about ibuprofen 400 mg caplets based only on their reading of the Drug Facts Label (DFL) and other information on the package.

03

Conditions studied

  • Patient Compliance

Browse trials for

Keywords

  • ibuprofen 400 mg
  • actual use
  • compliance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female at least 18 years of age (19 years of age in Alabama)
  • Subject reports taking over-the-counter (OTC) analgesics for pain or fever relief

Exclusion criteria

Exclusion Criteria:

  • Current government-issued identification (ID)
  • Pregnant or breastfeeding females
05

Study design

Phase
Phase 3
Masking
None (open label)
Enrollment
738 participants (actual)

Study arms

  • Experimental
    Ibuprofen caplet arm

    Drug: Ibuprofen 400 mg caplet

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Taking Greater Than (>) 1200 Milligram (mg) (>3 Caplets) on no More Than 2 Use Days During the Study

    Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if participants took more than 1200 mg (\>3 caplets) on either 0, 1 or 2 use days (where a use day was defined as a calendar day starting at 12:01 AM in which a participant received at least one dose of study medication), based on their diary. The behavior was considered acceptable if a participant exceeded the labelled daily dosing directions of taking more than 3 caplets per day, under the advice of a healthcare professional, based on information from the end of study follow-up interview.

    Time frame: Day 1 up to 30 days

Secondary outcomes

  1. Percentage of Participants Taking Greater Than (>) 400 mg (>1 Caplet) at a Time on no More Than 2 Dosing Occasions During the Study

    Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if the total number of dosing occasions (distinct usage date/time values from their diary) in which a participant received 2 or more caplets was 0, 1 or 2. The behavior was considered acceptable if a participant exceeded the labelled daily dosing directions of taking no more than 1 caplet per dose, under the advice of a healthcare professional, based on the end of study follow up interview.

    Time frame: Day1 up to 30 days

07

Results

Posted May 30, 2016

Participant flow

Participant flow — Overall Study
MilestoneIbuprofen
Started738
Completed635
Not completed103
Withdrew: Adverse event2
Withdrew: Protocol violation68
Withdrew: Lost to follow-up31
Withdrew: Other1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants Taking Greater Than (>) 1200 Milligram (mg) (>3 Caplets) on no More Than 2 Use Days During the Study

Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if participants took more than 1200 mg (\>3 caplets) on either 0, 1 or 2 use days (where a use day was defined as a calendar day starting at 12:01 AM in which a participant received at least one dose of study medication), based on their diary. The behavior was considered acceptable if a participant exceeded the labelled daily dosing directions of taking more than 3 caplets per day, under the advice of a healthcare professional, based on information from the end of study follow-up interview.

Time frame:
Day 1 up to 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Taking Greater Than (>) 1200 Milligram (mg) (>3 Caplets) on no More Than 2 Use Days During the Study
percentage of participantsIbuprofen
Percentage of Participants Taking Greater Than (>) 1200 Milligram (mg) (>3 Caplets) on no More Than 2 Use Days During the Study95.2 (93.6 to 96.8)
SecondaryPercentage of Participants Taking Greater Than (>) 400 mg (>1 Caplet) at a Time on no More Than 2 Dosing Occasions During the Study

Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if the total number of dosing occasions (distinct usage date/time values from their diary) in which a participant received 2 or more caplets was 0, 1 or 2. The behavior was considered acceptable if a participant exceeded the labelled daily dosing directions of taking no more than 1 caplet per dose, under the advice of a healthcare professional, based on the end of study follow up interview.

Time frame:
Day1 up to 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Taking Greater Than (>) 400 mg (>1 Caplet) at a Time on no More Than 2 Dosing Occasions During the Study
percentage of participantsIbuprofen
Percentage of Participants Taking Greater Than (>) 400 mg (>1 Caplet) at a Time on no More Than 2 Dosing Occasions During the Study84.4 (81.7 to 87.1)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibuprofen (Safety Population)—6/736 (0.8%)76/736 (10.3%)
Most frequent serious events
Most frequent serious events
EventIbuprofen (Safety Population)
Coronary artery occlusionCardiac disorders1/736
Atypical pneumoniaInfections and infestations1/736
CellulitisInfections and infestations1/736
PneumoniaInfections and infestations1/736
Joint dislocationInjury, poisoning and procedural complications1/736
NephrolithiasisRenal and urinary disorders1/736
Most frequent other events
Showing 10 of 52
Most frequent other events
EventIbuprofen (Safety Population)
NasopharyngitisInfections and infestations8/736
Gastrooesophageal reflux diseaseGastrointestinal disorders4/736
DizzinessNervous system disorders4/736
ConstipationGastrointestinal disorders3/736
NauseaGastrointestinal disorders3/736
InfluenzaInfections and infestations3/736
LacerationInjury, poisoning and procedural complications3/736
HeadacheNervous system disorders3/736
Abdominal discomfortGastrointestinal disorders2/736
DiarrhoeaGastrointestinal disorders2/736

Baseline characteristics

All participants who purchased at least 1 carton of study medication.

Age, Continuous
Age, Continuous(Years)Ibuprofen
Mean53.5 ± 13.7
Sex: Female, Male
Sex: Female, Male(Participants)Ibuprofen
Female412
Male326
08

Study locations

25 sites
  • Robert's Discount Pharmacy
    Hoover, Alabama 35226, United States
  • Pharmacy at the Pig
    McCalla, Alabama 35111, United States
  • Community Clinical Pharmacy
    Mesa, Arizona 85202, United States
  • Garden Drug
    Fort Lauderdale, Florida 33309, United States
  • Pill Box Pharmacy and Medical Supply
    Pembroke Pines, Florida 33026, United States
  • Summerfield Pharmacy
    Riverview, Florida 33569, United States
  • Sutton Family Pharmacy
    Dalton, Georgia 30721, United States
  • Wynn's Pharmacy Inc.
    Griffin, Georgia 30224, United States
  • Goodrich Pharmacy
    Andover, Minnesota 55304, United States
  • Goodrich Pharmacy
    Anoka, Minnesota 55303, United States
  • Goodrich Pharmacy
    Blaine, Minnesota 55434, United States
  • Goodrich Pharmacy
    Elk River, Minnesota 55330, United States
  • Cub Pharmacy Number 1924
    St. Louis Park, Minnesota 55426, United States
  • Albers' Specialty Pharmacy
    Kansas City, Missouri 64111, United States
  • Countryside Pharmacy
    Savannah, Missouri 64485, United States
  • Texas Road Pharmacy
    Monroe, New Jersey 08831, United States
  • Phil's Pills, Inc.
    Albuquerque, New Mexico 87110, United States
  • Total Health and Wellness Center of Taos
    Taos, New Mexico 87571, United States
  • Kroger Pharmacy #342
    Cary, North Carolina 27513, United States
  • Family Prescription Center
    Bethlehem, Pennsylvania 18015, United States
  • The Medicine Shoppe
    Bountiful, Utah 84010, United States
  • Northview Pharmacy
    Layton, Utah 84041, United States
  • Family Plaza Pharmacy
    West Jordan, Utah 84088, United States
  • Foothills Compounding Pharmacy
    Enumclaw, Washington 98022, United States
  • Ostrom Drugs
    Kenmore, Washington 98028, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2014
First posted
Nov 19, 2014
Start
Nov 2014
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
May 30, 2016
Last update
May 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02294019
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 19, 2014
Start date
Nov 2014
Primary completion
May 2015
Completion
May 2015
Results posted
May 30, 2016
Last update
May 30, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion